Ozempic and Wegovy contain the exact same active ingredient, semaglutide, made by the same manufacturer (Novo Nordisk). The core difference is what they’re approved to treat and how much you take. Ozempic is approved for type 2 diabetes, while Wegovy is approved for weight management and cardiovascular risk reduction. That distinction shapes everything from the dose you receive to whether your insurance will cover it.
Same Drug, Different Purpose
Semaglutide works by mimicking a natural hormone called GLP-1 that your body releases after eating. It enhances insulin release when blood sugar is high, reduces the amount of sugar your liver produces, and slows how quickly food leaves your stomach. That combination lowers blood sugar and makes you feel full longer, which is why the same molecule works for both diabetes and weight loss.
Ozempic is FDA-approved specifically for improving blood sugar control in adults with type 2 diabetes. In clinical trials, people taking Ozempic at its highest dose saw their average A1c (a measure of blood sugar over three months) drop by roughly 1.5 to 2.2 percentage points, depending on the study and comparison drug.
Wegovy has a broader set of approvals. It’s indicated for long-term weight management in adults with obesity, or in adults who are overweight with at least one weight-related health condition. It’s also approved for adolescents 12 and older with obesity. Beyond weight loss, Wegovy carries an approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults who already have heart disease along with obesity or overweight. Most recently, the FDA approved Wegovy for a form of fatty liver disease with moderate to advanced scarring.
The Doses Are Not the Same
This is one of the most practical differences. Ozempic tops out at 2.0 mg per week. Wegovy’s maintenance dose is 2.4 mg per week, roughly 20% higher. Both drugs are injected once weekly under the skin, typically in the stomach, thigh, or upper arm.
Both require a gradual dose increase to minimize side effects like nausea. With Ozempic, you generally start at 0.25 mg and step up over several weeks toward 1.0 or 2.0 mg. With Wegovy, the titration moves through 0.25, 0.5, 1.0, and 1.7 mg before reaching the 2.4 mg maintenance dose. That ramp-up period for Wegovy takes about 16 to 20 weeks.
Because the target dose differs, switching between the two isn’t as simple as swapping one pen for the other. Your prescriber needs to adjust the schedule if you’re transitioning.
The Pens Work Differently
Wegovy comes as a single-use, prefilled pen. Each pen contains one dose, and you discard it after injection. Ozempic uses a multi-dose pen that holds several weeks’ worth of medication. You attach a new needle tip for each injection and dial up your prescribed dose. Both require pen needles, and both are stored in the refrigerator before first use.
For some people, the single-use Wegovy pen feels simpler since there’s no dialing involved. Others prefer the Ozempic pen because it means fewer devices to keep track of each month.
Insurance Coverage Varies Widely
This is where the distinction between “diabetes drug” and “weight loss drug” hits your wallet hardest. Most private insurers and pharmacy benefit managers cover Ozempic when prescribed for type 2 diabetes, though prior authorization or step therapy requirements are common. Wegovy, classified as a weight management medication, faces much steeper coverage barriers.
Most private insurance companies and federal health programs do not cover weight loss drugs. Medicare has been explicitly barred by law from covering weight loss treatments since 2003, though legislative efforts to change that are ongoing. Without insurance, both drugs cost over $1,000 per month out of pocket. Some people with obesity but not diabetes have been prescribed Ozempic off-label for weight loss because it’s easier to get covered, but insurers have increasingly flagged and denied those claims.
If you do have coverage for one but not the other, it’s worth knowing that the two are not considered interchangeable at the pharmacy level. A prescription for Ozempic cannot be filled as Wegovy, or vice versa, even though the active ingredient is identical.
Side Effects Are Essentially Identical
Because both drugs are semaglutide, the side effect profile is the same. The most common issues are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These tend to be worst during dose increases and often improve as your body adjusts over several weeks. The slow titration schedule exists specifically to reduce these effects.
More serious but less common risks include inflammation of the pancreas, gallbladder problems, and kidney issues related to dehydration from prolonged vomiting or diarrhea. Both carry a boxed warning about a type of thyroid tumor seen in animal studies, though it’s unclear whether this risk applies to humans. People with a personal or family history of a specific thyroid cancer called medullary thyroid carcinoma should not take either drug.
Which One Gets Prescribed?
Your diagnosis determines which version a prescriber will reach for. If you have type 2 diabetes and need better blood sugar control, Ozempic is the standard choice. If your primary goal is weight loss or you have established cardiovascular disease alongside obesity, Wegovy is the appropriate option. Some people with type 2 diabetes who also need significant weight loss may benefit from the higher Wegovy dose, but that decision involves navigating both clinical judgment and insurance realities.
Neither drug is currently on the FDA’s shortage list, a notable improvement from the widespread supply disruptions that affected both medications through much of 2023 and 2024. Availability of specific dose strengths can still vary by pharmacy, so calling ahead before filling a prescription saves time.